The Big Pharmaceutical companies create medicines and devices for millions of people worldwide while making substantial profits. The Patent Medicines Pricing Review Board’s (PMPRB) 2011 Annual Report highlights that the investment of research and development (R&D) in Canada by these companies has not matched their commitment levels. The association representing the Big Pharma player, Canada’s Research-based Pharmaceutical Companies (Rx&D), pleads that a poor investment environment in Canada needs to be fixed so that they can effectively compete for corporate R&D dollars.
